JT
JDRF T1D Fund
Venture CapitalActiveA venture philanthropy fund exclusively devoted to finding and funding the best early-stage T1D commercial opportunities.
23
Investments
1
Exits
$100M
AUM
4.3%
Exit Rate
Get contact info, warm intros & fit scores
Sign up to unlock emails, Signal intro paths, and personalized fit analysis for JDRF T1D Fund.
Investment Thesis & Strategy
JDRF T1D Fund invests in early-stage companies with commercial opportunities in the Type 1 diabetes space. They focus on finding and funding the best companies in the industry.
Investment Activity
Deals per year over the last 8 years
1
20151
20161
20174
20182
20190
20200
20211
2022Portfolio Companies
Selected investments from their portfolio of 23 companies
S
Sprout Bio
Biotech · Seed, 2022
I
Imcyse
Biotech · Series B, 2019
A
Arecor Therapeutics
Biotech · Growth, 2019
T
Triumvira Immunologics
Biotech · Series A, 2018
S
Sernova Corp.
Biotech · Growth, 2018
D
Diamyd Medical
Biotech · Growth, 2018
P
Pancreas Regeneration
Biotech · Seed, 2018
P
Provention Bio
Biotech · Series A, 2017
B
Beta Bionics
Healthcare · Series B, 2016
C
Cellnovo
Healthcare · Growth, 2015
Notable Exits
CompanyTypeYearValue / Acquirer
Semma TherapeuticsAcquisition2019$950M
Frequently Asked Questions
JDRF T1D Fund focuses on Series A, Series B, Series C+ stage investments.